Metabolism and disposition of a potent group II metabotropic glutamate receptor agonist, in rats, dogs, and monkeys

Drug Metabolism and Disposition

Volumn 33, Issue 9, 2005, Pages 1373-1381

  James, Joyce K ^a   Nakamura, Masato ^b   Nakazato, Atsuro ^b   Zhang, Kanyin E ^a   Cramer, Merryl ^a   Brunner, Janice ^a   Cook, Jacquelynn ^a   Chen, Weichao G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 FLUORO 4 HYDROXYBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 AMINO 6 FLUORO 4 OXOBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; MGS 0025; MGS 0028; MGS 0034; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; CYTOSOL; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; ISOMER; LIVER CYTOSOL; MALE; METABOLITE; MICROSOME; NONHUMAN; ORDO; PLASMA; PREDICTION; PRIORITY JOURNAL; RAT; RHESUS MONKEY; SPECIES DIFFERENCE; URINARY EXCRETION;

ANIMALS; BICYCLO COMPOUNDS; CARBON RADIOISOTOPES; CELLS, CULTURED; CEREBELLUM; DICARBOXYLIC ACIDS; DOGS; EXCITATORY AMINO ACID AGONISTS; FECES; HUMANS; MACACA MULATTA; MALE; MICROSOMES, LIVER; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SPECIES SPECIFICITY; TELENCEPHALON; TISSUE DISTRIBUTION;

CANIS FAMILIARIS; MACACA MULATTA;

EID: 23944518395     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.004978     Document Type: Article

References (31)

1. Cartmell J, Monn JA, and Schoepp DD (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus D-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291:161-170.
2. Conn J-P and Pin PJ (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
3. Danysz W, Parson CG, Bresink I, and Quack G (1995) Glutamate in CNS disorders. Drug News Perspect 8:261-277.
4. Emile L, Mercken L, Apioe F, Pradier L, Bock M-D, Menager J, Clot J, Doble A, and Blanchard J-C (1996) Molecular cloning, functional expression, pharmacological characterization and chromosomal localization of the human metabotropic glutamate receptor type 3. Neuropharmacology 35:523-530.
5. Flor PJ, Lindauer K, Puttner I, Ruegg D, Lukic S, Knopfel T, and Kuhn R (1995) Molecular cloning, functional expression and pharmacological characterization of human metabotropic glutamate receptor type 2. Eur J Neurosci 7:622-629.
6. Forrest GL and Gonzalez B (2000) Carbonyl reductase. Chem-Biol Interact 129:21-40.
7. Gottlieb M, Wang Y, and Teichberg VI (2003) Blood-mediated scavenging of cerebrospinal fluid glutamate. J Neurochem 87:119-126.
8. Grillon C, Cordova J, Levine LR, and Morgan CA 3rd (2003) Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear potentiated startle paradigm in humans. Psychopharmacology 168:446-454.
9. Helton DR, Taizzano JP, Monn JA, Schoepp DD, and Kallman MJ (1997) LY354740: a metabotropic glutamate receptor agonist which ameliorates systems of nicotine withdrawal in rats. Neuropharmacology 36:1511-1516.
10. Helton DR, Taizzano JP, Monn JA, Schoepp DD, and Kallman MJ (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651-660.
11. Hermans JJ and Thijssen HH (1992) Stereoselective acetonyl side chain reduction of warfarin and analogs. Partial characterization of two cytosolic carbonyl reductases. Drug Metab Dispos 20:268-274.
12. Johnson JT, Mattiuz EL, Chay SH, Herman JL, Wheeler WJ, Kassahun K, Swanson SP, and Phillips DL (2002) The disposition, metabolism and pharmacokinetics of a selective metabotropic glutamate receptor agonist in rats and dogs. Drug Metab Dispos 30:27-33.
13. Kammermeier PJ, Davis MI, ad Ikeda SR (2003) Specificity of metabotropic glutamate receptor 2 coupling to G proteins. Mol Pharmacol 63:183-191.
14. Levine LR, Gaydos B, Sheehan DV, Goddard A, Feighner J, Potter WZ, and Shoepp DD (2003) LY354740, an MGLU2/3 receptor agonist, reduces CO2-induced panic anxiety in patients diagnosed with DSM-IV panic disorder. Poster, New Clinical Drug Evaluation Unit, 43rd National Meeting, Boca Raton, FL, National Institute of Mental Health, Bethesda, MD.
15. Makoff A, Volpe F, Lelchuk R, Harrington K, and Emson P (1996) Molecular characterization and localization of human metabotropic glutamate receptor type 3. Mol Brain Res 40:165-170.
16. Milovanovic DR, Dejanovic SD, Mihajlovic G, and Jankovic SM (2002) A concise review of glutamatergic neurotransmission. Epitheorese Klinikes Farmakologias Kai Farmakokinetikes, International Edition 15:125-136.
17. Moghaddam B and Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science (Wash DC) 28:1349-1352.
18. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, et al. (1997) Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6- dicarboxylic acid (LY354740): a potent, selective and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528-537.
19. Nakanishi S (1992) Molecular diversity of glutamate receptors and implications for brain function. Science (Wash DC) 258:597-603.
20. Nakanishi S and Masu M (1994) Molecular diversity and functions of glutamate receptors. Annu Rev Biophys Biomol Struct 23:319-348.
21. Nakazato A, Kumagai T, Sakagami K, Yoshikawa R, Suzuki Y, Chaki S, Ito H, Taguchi T, Nakanishi S, and Okuyama S (2000) Synthesis, SARs, and pharmacological characterization of 2-animo-3 or 6-fluorobicyclo[3.1.0]hexane-2, 6-dicarboxylic acid derivatives as potent, selective and orally active group II metabotropic glutamate receptor agonists. J Med Chem 43:4893-4909.
22. Obach RS, Baxter JG, Liston TE, Silber M, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
23. Oldendorf WH and Szabo J (1976) Amino acid assignment to one of three blood-brain barrier amino acid carriers. Am J Physiol 230:94-98.
24. Oppermann UCT and Maser E (2000) Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology 144:71-81.
25. Pin J-P, De Colle C, Bessis A-S, and Acher F (1999) New Perspectives for the development of selective metabotropic glutamate receptor ligands. Eur J Pharm 375:277-294.
26. Pin J-P and Duvoisin R (1995) The metabotropic glutamate receptors: structure and function. Neuropharmacology 34:1-26.
27. Schoepp DD, Jane DE, and Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431-1476.
28. Schoepp DD, Wright RA, Levine LR, Gaydos B, and Potter WZ (2003) LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6:189-197.
29. Swanson CJ and Schoepp DD (2002) The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats. J Pharmacol Exp Ther 303:919-927.
30. Takamori K, Shiho S, Chaki S, and Tanaka M (2003) Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MGS0028 on conditioned avoidance responses in the rat. Life Sci 23:1721-1728.
31. Zlokovic BV, McComb JG, Perlmutter L, Welss MH, and Davson H (1992) Neuroactive peptides and amino acids at the blood-brain barrier: possible implications for drug abuse, in Bioavailability of Drug to the Brain and the Blood-Brain Barrier. NIDA Research Monograph 120 (Frankenheim J and Brown RM eds) pp 26-42, National Institute on Drug Abuse, Rockville, MD.